Alpha 2.0
Login Register
» Authors » Adrianus J de Langen

Adrianus J de Langen

Explore the profile of Adrianus J de Langen including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 68
Citations 1941
Followers 0
Related Specialties
Oncology
Nuclear Medicine
Pulmonary Medicine
Top 10 Co-Authors
Egbert F Smit
Otto S Hoekstra
Ronald Boellaard
Kim Monkhorst
Erik Thunnissen
Idris Bahce
Sayed M S Hashemi
Anna-Larissa N Niemeijer
Anne-Marie C Dingemans
Michel M van den Heuvel
Published In
J Nucl Med
Lung Cancer
Clin Cancer Res
J Thorac Oncol
Cancers (Basel)
Affiliations
Soon will be listed here.
Recent Articles
11.
A phase 2 trial combining afatinib with cetuximab in patients with EGFR exon 20 insertion-positive non-small cell lung cancer
van Veggel B, van der Wekken A, Paats M, Hendriks L, Hashemi S, Daletzakis A, et al.
Cancer . 2023 Oct; 130(5):683-691. PMID: 37905752
Background: Epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations are the third most common EGFR mutations in patients with non-small cell lung cancer (NSCLC) and are associated with...
12.
A comprehensive overview of the heterogeneity of EGFR exon 20 variants in NSCLC and (pre)clinical activity to currently available treatments
Zwierenga F, van Veggel B, van den Berg A, Groen H, Zhang L, Groves M, et al.
Cancer Treat Rev . 2023 Oct; 120:102628. PMID: 37797348
Activating EGFR mutations are commonly observed in non-small cell lung cancer (NSCLC). About 4-10 % of all activating epidermal growth factor receptor (EGFR) mutations are heterogenous in-frame deletion and/or insertion...
13.
Clinical Relevance of High Plasma Trough Levels of the Kinase Inhibitors Crizotinib, Alectinib, Osimertinib, Dabrafenib, and Trametinib in NSCLC Patients
Lin L, Barkman H, Smit E, de Langen A, Steeghs N, Beijnen J, et al.
Ther Drug Monit . 2023 Jun; 46(1):73-79. PMID: 37348074
Background: the study aims to evaluate whether high plasma trough levels of the kinase inhibitors (K.I.s) crizotinib, alectinib, osimertinib, dabrafenib, and trametinib were associated with a higher risk of toxicity...
14.
Blood platelet RNA profiles do not enable for nivolumab response prediction at baseline in patients with non-small cell lung cancer
Muller M, Best M, van der Noort V, Hiltermann T, Niemeijer A, Post E, et al.
Tumour Biol . 2023 Jun; 46(s1):S327-S340. PMID: 37270827
Background: Anti-PD-(L)1 immunotherapy has emerged as a promising treatment approach for non-small cell lung cancer (NSCLC), though the response rates remain low. Pre-treatment response prediction may improve patient allocation for...
15.
Chemotherapy for patients with EGFR-mutated NSCLC after progression on EGFR-TKI's: Exploration of efficacy of unselected treatment in a multicenter cohort study
Steendam C, Ernst S, Badrising S, Paats M, Aerts J, de Langen A, et al.
Lung Cancer . 2023 May; 181:107248. PMID: 37216839
Objectives: In patients with Epidermal Growth Factor Receptor (EGFR)-mutated non-small cell lung (NSCLC) chemotherapy remains standard of care after progression on EGFR-tyrosine kinase inhibitors (TKIs). With the development of anti-angiogenic...
16.
Early response evaluation of PD-1 blockade in NSCLC patients through FDG-PET-CT and T cell profiling of tumor-draining lymph nodes
Borm F, Smit J, Bakker J, Wondergem M, Smit E, de Langen A, et al.
Oncoimmunology . 2023 May; 12(1):2204745. PMID: 37123045
Better biomarkers for programmed death - (ligand) 1 (PD-(L)1) checkpoint blockade in non-small cell lung cancer (NSCLC) are needed. We explored the predictive value of early response evaluation using Fluor-18-deoxyglucose...
17.
Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, multicenter phase IV randomized controlled trial (ADAPT ALEC)
Meertens M, Muntinghe-Wagenaar M, Sikkema B, Lopez-Yurda M, Retel V, Paats M, et al.
Front Oncol . 2023 Mar; 13:1136221. PMID: 36969063
Background: Alectinib is first-line therapy in patients with stage IV non-small cell lung carcinoma (NSCLC) and an anaplastic lymphoma kinase (ALK) fusion. A shorter median progression-free survival (mPFS) was observed...
18.
Tobacco Smoking-Related Mutational Signatures in Classifying Smoking-Associated and Nonsmoking-Associated NSCLC
Ernst S, Mankor J, van Riet J, von der Thusen J, Dubbink H, Aerts J, et al.
J Thorac Oncol . 2022 Dec; 18(4):487-498. PMID: 36528243
Introduction: Patient-reported smoking history is frequently used as a stratification factor in NSCLC-directed clinical research. Nevertheless, this classification does not fully reflect the mutational processes in a tumor. Next-generation sequencing...
19.
Detection and localization of early- and late-stage cancers using platelet RNA
In t Veld S, Arkani M, Post E, Antunes-Ferreira M, DAmbrosi S, Vessies D, et al.
Cancer Cell . 2022 Sep; 40(9):999-1009.e6. PMID: 36055228
Cancer patients benefit from early tumor detection since treatment outcomes are more favorable for less advanced cancers. Platelets are involved in cancer progression and are considered a promising biosource for...
20.
Exposure-Response Analysis of Osimertinib in EGFR Mutation Positive Non-Small Cell Lung Cancer Patients in a Real-Life Setting
Boosman R, Jebbink M, Veldhuis W, Groenland S, van Veggel B, Moeskops P, et al.
Pharm Res . 2022 Aug; 39(10):2507-2514. PMID: 35978149
Background: Osimertinib, an irreversible inhibitor of the epidermal growth factor receptor (EGFR) is an important drug in the treatment of EGFR-mutation positive non-small cell lung cancer (NSCLC). Clinical trials with...